AI for Gene Therapy and Disease Characterization

Featured Products

Welcome to our state-of-the-art AI repertoire, where innovation meets precision. We offer a curated selection of advanced AI products designed specifically for different stages of gene therapy and disease characterization to meet the highest standards of scientific excellence and innovation.

UPNA

State-of-the-art high-throughput and generalizable AI for molecular interaction (drug-target, protein-protein, and protein-peptide) prediction.

Dis2Vec

A foundation model for disease representation learning. The Applications include target identification and repurposing, disease characterization, and drug repurposing and discovery.

Our Services

AI Consultation

We provide consultation services to biotech and pharmaceutical companies to provide expert opionion and designs for AI solutions tailored to the customer needs.

AI Deployment

We deploy and validate end-to-end AI pipelines comprising state-of-the-art models handpicked for your task of interest.

AI Development

We design custom AI architectures and train models using both public and proprietary experimental data to address the specific needs of our clients.

About
our company

BioClarity AI is a Boston-based biotech company founded by Dr. Ayan Chatterjee, advancing AI-powered solutions for gene therapy and disease characterization. The company builds lightweight, generalizable machine learning models for AAV capsid design, regulatory element optimization, and molecular network analysis. Ayan is a researcher in graph machine learning with a focus on biological networks, and previously worked at NVIDIA, AstraZeneca, and Google DeepMind.